Clinical trial · Interventional
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
SAbR-Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
NCT02986867CI-TRIAL-00036447completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR. Tumor core biopsies will be processed and analyzed as described above. Medical records electronic medical records will be used to collect demographic and medical information and imaging studies.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Carcinoma in Situ | — | UNRESOLVED | — |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Urothelial Carcinoma | Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SAbR Treatment of Lesions | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SAbR
- description
- SAbR treatment of lesions
- interventionNames
- Radiation: SAbR Treatment of Lesions
Primary outcomes (4)
- measure
- Comparison of immune checkpoint treated tumors
- timeFrame
- 36 months
- description
- Compare cGAMP levels, interferon response gene expression and phospho-STING in tumors of immune checkpoint treated patients.
- measure
- SAbR effects on cGAMP in tumors
- timeFrame
- 36 months
- description
- Number of participants with SAbRrelated tumor changes indicated by cGAMP in comparison to Baseline.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic diagnosis of advanced/metastatic urothelial carcinoma, melanoma, or cervical carcinoma. * Planned treated with SAbR. * Age greater than or equal to 18 years. * Lesion to receive SAbR safely accessible for core biopsy-mass \>1.5cm diameter and located in node, liver, or soft tissues. * Hgb \>10g/dL before or after transfusion. * Platelets \>50,000/L * INR \<1.5 * If contrast enhanced CT needed to locate the lesion for core biopsy, then derived creatinine clearance \>30cc/min * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Prior radiation therapy to target lesion. * Target lesion not safely accessible for core biopsies.
References
Publications (0)
Data not yet available
No reference posted for this study.